## PATENT CASE IN01481KB

Examiner: To Be Assigned

Art Unit: To Be Assigned

Date: July 29, 2003

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Anandan Palani et al

For Patent For:

PIPERIDINE DERIVATIVES USEFUL

AS CCR5 ANTAGONISTS

Serial No.: To Be Assigned

Filing Date: July 29, 2003

Schering-Plough Corporation Kenilworth, New Jersey 07033-0530

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Sir:

Submitted herewith is Applicants' PTO 1449 form, and a copy of Applicants' Information Disclosure Statement from Applicants' parent Application Serial No. 10/229,466 filed August 28, 2002.

The references cited in the present PTO 1449 form were cited in the PTO 1449 form submitted in Applicants' parent Application, with the exception of Reference AK which is a newly cited reference.

Since the cited references were cited in Applicants' parent Application, copies of the references are not being submitted herewith. The Examiner is requested to notify the undersigned if another copy of the references is desired.

Applicant requests that the cited documents be made of record in the above-identified Application.

Respectfully submitted,

Robert L. Danntein Robert L. Bernstein Reg. No. 46,020

Attorney for Applicants

FORM PTO-1449  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE					ATTY. DOCKET NO.: IN01481KB		SERIAL NO.: To Be Assigned		
INFORMATION DISCLOSURE STATEMENT					APPLICANT:				
BY APPLICANT Anandan Palani et al.									
(Use several sheets if necessary)					FILING DATE:		GROUP:		
(Ose several sheets if fieldssary)					July 21, 2003 To Be Assigned				
				ATENT DOCUM					
*EXAMINER INITIAL		DOCUMENT DATE NAM NUMBER					SUB- FILING DATE IF CLASS APPROPRIATE		
	AΑ	5,952,349	09/14/99	Theodros Asberom et al.		514	316		
	AB					<del></del>	ļ	<u> </u>	
	AC							ļ	
·	AD		<b> </b>				ļ	<u> </u>	<del></del>
	AE						<u> </u>	<del>                                     </del>	7
	AF		<del></del>					<del> </del>	
	AG		<del> </del>		<del></del> -		<del> </del>	<del> </del>	
}	AH		<del> </del>	<del></del>	<del></del>	<del> </del>	<del></del>	<del>├</del> -	
<u> </u>	AJ		ļ		<del></del>			<del>                                     </del>	
	IAU		<u> </u>	<u>L</u>		<u> </u>	L	<u> </u>	
FOREIGN PATENT DOCUMENTS									
		DOCUMENT	DATE	COUNTRY		CLASS	SUB-		LATION
		NUMBER	ļ				CLASS	YES	NO
	AK	WO 02/081449	10/17/02	PCT		C07D	211/58	ļ	<del></del> -
	AL	WO 98/01425	01/15/98	PCT		C07D	211/58	<del> </del>	
	AM	EP 0 855 999	10/04/01	Europe		C07D	211/44	<del>                                     </del>	
	AN	WO 97/24324	07/10/97	PCT		C07D	211/44	<del> </del>	-
	AO	EP 0 151 824	08/21/85	Europe		C07D	471/04	├	1
<u> </u>	AP	WO 01/30348 WO 01/77101	05/03/01 10/18/01	PCT PCT		A61K	31/445	}	<del> </del>
	AQ AR	WO 01/77101 WO 02/081449	10/18/01	PCT	<del>_</del>	C07D	401/04 211/58	<del> </del>	<del> </del>
<del></del>								L	<u> </u>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)									
	AS	Anandan Palani et al., "Discovery of 4-[(Z)-(4-Bromophenyl)-(ethoxyimino)methyl]-1'-[(2,4							
		dimethyl-3-pyridinyl)carbonyl]-4'-methyl-1,4'-bipiperidine N-Oxide (SCH 351125): An Orally							
ľ		Bioavailable Human CCR5 Antagonist for the Treatment of HIV Infection", Journal of Medicinal Chemistry, vol. 44, No. 21, October 11, 2001, pgs. 3339-3342							
	AT	Onemiany, voi. 44, i	40. Z 1, OCIC	<u>, , 2001, pgs</u>	. 0003-0042				
	ΑÜ								
	AV	-							
	AW						<del></del>		
	AX								
EXAMINER DATE CONSIDERED									
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line									
through citation if not in conformance and not considered. Include copy of this form with next communication to									
applicant.									